^
    2d
    Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2. (PubMed, ESMO Open)
    Olaparib demonstrated meaningful clinical activity across different cancer types with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • ATRX (ATRX Chromatin Remodeler) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD21 (RAD21 Cohesin Complex Component) • DDR2 (Discoidin domain receptor 2) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • RAD52 (RAD52 Homolog DNA Repair Protein) • FANCE (FA Complementation Group E) • GEN1 (GEN1 Holliday junction 5' flap endonuclease) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
    |
    BRCA2 mutation • BRCA1 mutation • HRD • ARID1A mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation • CHEK1 mutation
    |
    Lynparza (olaparib)
    2d
    From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. (PubMed, Drugs Real World Outcomes)
    Genomic testing application remained limited and uneven across centers. Most eligible patients received olaparib; TN patients seemed to benefit most.
    Clinical • Journal • Real-world evidence • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib)
    3d
    Phase I Comparative Bioavailability Study (clinicaltrials.gov)
    P1, N=197, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Lynparza (olaparib)
    3d
    LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. (PubMed, Genome Biol)
    Our findings unveil a novel regulatory mechanism of L1 m6A that governs the DNA damage repair response, providing a potential strategy of targeting METTL3 in combination with PARPi for cancer therapy.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • METTL3 (Methyltransferase Like 3)
    |
    BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib)
    3d
    Severe anemia as a risk factor in Japanese patients with ovarian cancer receiving olaparib: a retrospective study. (PubMed, BMC Cancer)
    Prior PLD therapy, impaired renal function, and pre-existing anemia substantially increased the risk of severe anemia during olaparib treatment. These findings highlight the need for risk-adaptive monitoring strategies and proactive management in patients with high risk for severe anemia. Further studies with larger cohorts of patients with renal impairment are recommended to support dose-adjustment strategies and optimize treatment safety.
    Retrospective data • Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Lynparza (olaparib) • pegylated liposomal doxorubicin
    5d
    JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models. (PubMed, Br J Cancer)
    These results suggest the scientific rationale for further clinical development of JPI-547 for treating both PARP inhibitor-sensitive patients and those resistant to first-generation PARP inhibitors in BRCA-mutated cancers.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • nesuparib (JPI-547)
    5d
    Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial. (PubMed, Int J Gynecol Cancer)
    These data confirm that the use of olaparib as long-term maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer is tolerable. Adverse events occurred early, were manageable, and few occurred with late onset.
    Clinical • P3 data • Journal • Adverse events • BRCA Biomarker • PARP Biomarker • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    5d
    FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=85, Active, not recruiting, Fusion Pharmaceuticals Inc. | Trial completion date: Aug 2030 --> May 2027 | Trial primary completion date: Jan 2030 --> May 2027
    Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation • FOLH1 positive
    |
    Lynparza (olaparib) • FPI-2265
    6d
    A small molecule disrupts G4-STAT1 interaction and synergizes with olaparib to drive cancer cell death. (PubMed, Nucleic Acids Res)
    Furthermore, BER/COP exhibited a pronounced synergistic effect with olaparib in inducing colon cancer cell death by disrupting DNA repair pathways and intensifying DNA damage. Collectively, our findings reveal a novel epigenetic mechanism of BLM gene upregulation mediated by BLM-G4-STAT1 interaction and suggest that the combination therapy of G4 stabilizers with poly(ADP) ribose polymerase (PARP) inhibitors is a promising strategy for treating complex cancers.
    Journal • PARP Biomarker
    |
    BLM (BLM RecQ Like Helicase) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    Lynparza (olaparib)
    6d
    Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling. (PubMed, NPJ Precis Oncol)
    In this study, we evaluated a novel liquid biopsy platform based on circulating cell-free DNA active chromatin (cfDNAac) profiling to identify baseline biomarkers associated with clinical benefit rate (CBR) in 30 LMS patients treated with durvalumab plus olaparib or cediranib. In this analysis, cfDNAac profiling represents a promising non-invasive strategy to predict clinical benefit from CPI-based therapy in LMS. Prospective validation in independent cohorts is warranted to clarify its clinical utility.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    6d
    Expert consensus on the clinical application of PARP inhibitors in breast cancer (2025 edition) (PubMed, Zhonghua Zhong Liu Za Zhi)
    Currently, PARP inhibitors such as olaparib and fluzoparib have been approved for clinical use. Based on the latest evidence-based medical data, the Professional Committee on Clinical Research of Oncology Drugs, China Anti-Cancer Association, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs and Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center have jointly organized and invited domestic oncology experts with rich diagnosis and treatment experience as well as relevant interdisciplinary experts to compile the "Expert consensus on the clinical application of PARP inhibitors in breast cancer (2025 edition)". This consensus aims to provide guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, with the goal of supporting clinical practice.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • AiRuiYi (fluzoparib)
    6d
    SCS-Lung01: Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Sichuan University | Trial completion date: Mar 2027 --> Oct 2028 | Trial primary completion date: Jun 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Lynparza (olaparib) • cisplatin • etoposide IV • Cejemly (sugemalimab)